Research · 2026-03-24
Harvard/McLean Researchers Publish First Case of 7-OH Use Disorder Successfully Treated With Buprenorphine
Source: Journal of Addiction Medicine
Why it matters
Clinicians nationwide are seeing 7-hydroxymitragynine (7-OH) use disorder in patients but have had almost no peer-reviewed guidance on how to treat it — until now. This Harvard/McLean Hospital case report provides the first published roadmap for managing 7-OH withdrawal and dependence.
The big picture
As concentrated 7-OH products flood gas stations and convenience stores, addiction medicine physicians are encountering a new and poorly understood clinical entity. While 7-OH is chemically related to kratom, it binds to opioid receptors at far higher potency and its withdrawal and dependence profile had not been formally described in major peer-reviewed literature until this case.
Key findings
- 7-OH (7-hydroxymitragynine) is present in small amounts in natural kratom but is being sold in concentrated form at gas stations and online, exposing users to a high-potency opioid
- A man in his 30s was hospitalized at McLean Hospital for intensive 7-OH use disorder treatment
- Opioid withdrawal symptoms emerged within just 8 hours of cessation — rapid onset comparable to short-acting opioids
- Withdrawal was stabilized with methadone 50 mg over 36 hours, then the patient was transitioned to buprenorphine 16 mg per day via low-dose induction
- By discharge from residential aftercare, cravings had resolved and co-occurring depression had improved
- Authors conclude that standard medications for opioid use disorder (MOUD) are effective for 7-OH dependence
What they say
7-HMG is a widely available, largely unregulated, underrecognized substance with potency at the opioid receptor that may increasingly concern clinicians and policymakers. More research is needed to characterize the effects of 7-HMG in humans and guide management. — Hendler et al., McLean Hospital/Harvard Medical School
Bottom line
This Harvard/McLean case confirms that 7-OH causes true opioid use disorder with rapid withdrawal onset, and that buprenorphine is an effective treatment — critical knowledge for any clinician encountering these patients.